Buprenorphine Prior Authorization Bans: Do They Improve Treatment Adherence?

March 6, 2026 Ananya Mittal - World Editor

State laws designed to ease access to buprenorphine, a crucial medication for treating opioid use disorder, may not be achieving their intended effect of improved long-term treatment retention, according to a recent study. Whereas removing insurance requirements for prior authorization aims to streamline access, research suggests it hasn’t translated into significantly more patients staying in treatment for the recommended 180 days or longer.

Buprenorphine and the Challenges of Treatment Adherence

Buprenorphine works by relieving opioid cravings and managing withdrawal symptoms, offering a vital pathway to recovery for individuals struggling with opioid addiction. However, simply getting a prescription filled isn’t enough. Consistent adherence to medication is a significant hurdle in opioid use disorder treatment. The new research, published in JAMA Network Open, adds a layer of complexity to the ongoing effort to improve treatment outcomes.

The study, led by researchers analyzing private insurance claims data from 49 states and the District of Columbia, examined the impact of state laws prohibiting prior authorization for buprenorphine. Prior authorization is a process where insurance companies require doctors to obtain approval before prescribing certain medications, often involving paperwork and potential delays. Advocates for eliminating these requirements argue they create unnecessary barriers to timely treatment.

Study Design and Findings

Researchers used a difference-in-differences design, comparing buprenorphine treatment retention rates in states that implemented prior authorization prohibitions with those that did not. The analysis included data from over 22,900 patients aged 18 to 64 who initiated buprenorphine treatment between January 1, 2015, and June 1, 2022. The primary outcome measured was whether a patient continued buprenorphine treatment for at least 180 days.

The findings revealed that adopting prior authorization prohibitions was not associated with significant changes in buprenorphine treatment retention rates (effect estimate, 0.007; 95% CI, -0.044 to 0.059; P = .78). Approximately 30.4% of patients in the study reached the 180-day retention threshold, a figure that remained largely unchanged by the policy changes. This suggests that while removing administrative hurdles may improve initial access, it doesn’t necessarily address the underlying factors contributing to treatment discontinuation.

Beyond Access: Factors Influencing Treatment Retention

The study highlights the multifaceted nature of opioid use disorder treatment. While access is undoubtedly crucial, it’s only one piece of the puzzle. Numerous factors can influence a patient’s ability to stay in treatment, including:

  • Social determinants of health: Factors like housing instability, food insecurity, and lack of transportation can significantly impact treatment adherence.
  • Psychological factors: Co-occurring mental health conditions, such as depression and anxiety, can create it more challenging to engage in and benefit from treatment.
  • Treatment setting and support: The quality of care, the availability of counseling and support groups, and the strength of the patient-provider relationship all play a role.
  • Stigma: The stigma associated with opioid use disorder can discourage individuals from seeking and continuing treatment.

Researchers noted that the study focused on patients with private insurance, and the findings may not be generalizable to those with public insurance or no insurance. The study did not differentiate between branded and generic buprenorphine, potentially masking variations in retention rates based on medication type.

Telehealth Access and Opioid Treatment

The findings arrive at a time when access to medication-assisted treatment (MAT) for opioid use disorder is under scrutiny. Recent debates surrounding telehealth regulations have underscored the importance of flexible access options. As Weill Cornell Medicine researchers reported in March 2025, restricting telehealth prescriptions for buprenorphine could prevent thousands from accessing this life-saving medication. The temporary suspension of in-person examination requirements during the COVID-19 pandemic significantly expanded access to telehealth buprenorphine, particularly in rural areas and for individuals with transportation challenges. The study estimated that requiring in-person visits could have prevented 4,500 patients from receiving treatment between 2020, and 2022.

What Does This Mean for Policy and Practice?

The new research on prior authorization prohibitions suggests that policymakers should avoid relying on single-pronged solutions to address the opioid crisis. Simply removing administrative barriers may not be enough to improve treatment outcomes. A more comprehensive approach is needed, one that addresses the complex interplay of factors influencing treatment retention.

This includes investing in:

  • Integrated care models: Combining buprenorphine treatment with mental health services and social support.
  • Community-based programs: Expanding access to treatment in underserved areas.
  • Efforts to reduce stigma: Promoting understanding and compassion for individuals with opioid use disorder.
  • Further research: Investigating the specific factors that contribute to treatment retention and identifying effective interventions.

The findings also underscore the importance of ongoing monitoring and evaluation of policies aimed at improving access to opioid use disorder treatment. It’s crucial to assess not only whether policies increase initial access but also whether they lead to sustained engagement in treatment and improved long-term outcomes.

Next Steps: Refining Treatment Strategies

The current research highlights the need for a more nuanced understanding of the barriers to buprenorphine treatment retention. Future studies should explore the effectiveness of different interventions aimed at improving adherence, such as care coordination, peer support, and motivational interviewing. Research is needed to identify the specific needs of different patient populations and tailor treatment approaches accordingly. Continued surveillance of treatment retention rates, coupled with rigorous evaluation of policy changes, will be essential to inform evidence-based strategies for combating the opioid crisis.